新型肥胖生物标志物作为CKD患者死亡率预测因素:与传统人体测量方法进行比较分析
1Department of Urology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, PR China.
Renal failure
|January 6, 2026
概括
与其他肥胖指标相比,身体形状指数 (ABSI) 是慢性病 (CKD) 患者死亡率的优异预测指标. ABSI显示了常规CKD风险评估的重大潜力.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 生物标志物 生物标志物
背景情况:
- 慢性病 (CKD) 与死亡风险增加有关.
- 传统的肥胖指标,如BMI和WC,在预测CKD的结果方面存在局限性.
- 新型肥胖生物标志物,身体形状指数 (ABSI) 和身体圆度指数 (BRI),需要进一步调查它们在CKD的预后价值.
研究的目的:
- 评估ABSI和BRI对成年CKD患者所有原因和心血管疾病 (CVD) 死亡率的预测能力.
- 为了比较ABSI和BRI与传统肥胖指标 (BMI,WC) 在预测死亡风险方面的表现.
- 评估ABSI,BRI和CKD队列中的死亡率之间的剂量反应关系.
主要方法:
- 一项队列研究分析了来自国家健康和营养检查调查 (1999-2018) 的6577名成年CKD参与者.
- 考克斯比例危险回归分析被用来确定ABSI和BRI的预后值,用于所有原因和心血管疾病死亡率.
- 使用时间依赖的接收器操作特征 (ROC) 曲线来比较ABSI,BRI,BMI和WC的预测性能.
主要成果:
- 在CKD队列中,经历了2,532例死亡 (31.7%),其中包括921例心血管疾病死亡,平均90个月.
- 与最低四分位数相比,ABSI的最高四分位数与所有原因 (3.320) 和心血管疾病死亡率 (3.796) 的危险比率显著更高.
- 在大多数随访期间,ABSI在预测所有原因和心血管疾病死亡率方面始终优于BRI,BMI和WC.
结论:
- ABSI是一种有前途且优异的肥胖生物标志物,用于预测美国成人患有CKD的全因和心血管疾病死亡风险.
- 这些发现支持将ABSI纳入常规预后评估中,用于CKD患者.
- ABSI显示出与死亡率的线性剂量反应关系,而BRI显示出非线性关联.
相关概念视频
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
185
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
185
01:21Drug Dosing: Obese Patients
217
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
217
01:25Chronic Kidney Disease I: Introduction
556
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
556
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
235
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
235
01:28Chronic Kidney Disease III: Interprofessional Care
333
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
333
01:24Chronic Kidney Disease II: Clinical Manifestations
543
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
543